These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 34336636)
21. The prognostic value of progesterone receptor status in meningiomas. Roser F; Nakamura M; Bellinzona M; Rosahl SK; Ostertag H; Samii M J Clin Pathol; 2004 Oct; 57(10):1033-7. PubMed ID: 15452155 [TBL] [Abstract][Full Text] [Related]
22. Meningiomas Display a Specific Immunoexpression Pattern in a Rostrocaudal Gradient: An Analysis of 366 Patients. Ülgen E; Bektaşoğlu PK; Sav MA; Can Ö; Danyeli AE; Hızal DB; Pamir MN; Özduman K World Neurosurg; 2019 Mar; 123():e520-e535. PubMed ID: 30503291 [TBL] [Abstract][Full Text] [Related]
23. Clinicopathological characteristics, hormone receptor status and matrix metallo-proteinase-9 (MMP-9) immunohistochemical expression in spinal meningiomas. Barresi V; Alafaci C; Caffo M; Barresi G; Tuccari G Pathol Res Pract; 2012 Jun; 208(6):350-5. PubMed ID: 22494536 [TBL] [Abstract][Full Text] [Related]
24. Association of apparent diffusion coefficient with Ki-67 proliferation index, progesterone-receptor status and various histopathological parameters, and its utility in predicting the high grade in meningiomas. Bozdağ M; Er A; Ekmekçi S Acta Radiol; 2021 Mar; 62(3):401-413. PubMed ID: 32397733 [TBL] [Abstract][Full Text] [Related]
25. Proliferation and progesterone receptor status in benign meningiomas are not age dependent. Roser F; Nakamura M; Ritz R; Bellinzona M; Dietz K; Samii M; Tatagiba MS Cancer; 2005 Aug; 104(3):598-601. PubMed ID: 15952201 [TBL] [Abstract][Full Text] [Related]
26. 1p/14q co-deletion: A determinant of recurrence in histologically benign meningiomas. Kakkar A; Kumar A; Das A; Pathak P; Sharma MC; Singh M; Suri A; Sarkar C; Suri V Indian J Pathol Microbiol; 2015; 58(4):433-8. PubMed ID: 26549062 [TBL] [Abstract][Full Text] [Related]
27. Malignant potential of skull base versus non-skull base meningiomas: clinical series of 1,663 cases. Cornelius JF; Slotty PJ; Steiger HJ; Hänggi D; Polivka M; George B Acta Neurochir (Wien); 2013 Mar; 155(3):407-13. PubMed ID: 23318687 [TBL] [Abstract][Full Text] [Related]
29. Recurrence/Regrowth in Grade I Meningioma: How to Predict? de Carvalho GTC; da Silva-Martins WC; de Magalhães KCSF; Nunes CB; Soares AN; Tafuri LSA; Simões RT Front Oncol; 2020; 10():1144. PubMed ID: 32903787 [TBL] [Abstract][Full Text] [Related]
30. Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression. Abdelzaher E; El-Gendi SM; Yehya A; Gowil AG Br J Neurosurg; 2011 Dec; 25(6):707-13. PubMed ID: 20979437 [TBL] [Abstract][Full Text] [Related]
31. Is progesteron receptor status really a prognostic factor for intracranial meningiomas? Iplikcioglu AC; Hatiboglu MA; Ozek E; Ozcan D Clin Neurol Neurosurg; 2014 Sep; 124():119-22. PubMed ID: 25036873 [TBL] [Abstract][Full Text] [Related]
32. Differential Tumor Progression Patterns in Skull Base Versus Non-Skull Base Meningiomas: A Critical Analysis from a Long-Term Follow-Up Study and Review of Literature. Savardekar AR; Patra DP; Bir S; Thakur JD; Mohammed N; Bollam P; Georgescu MM; Nanda A World Neurosurg; 2018 Apr; 112():e74-e83. PubMed ID: 29258946 [TBL] [Abstract][Full Text] [Related]
33. Long-term follow up of progesterone receptor status in benign meningioma: a prognostic indicator of recurrence? Fewings PE; Battersby RD; Timperley WR J Neurosurg; 2000 Mar; 92(3):401-5. PubMed ID: 10701525 [TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical expression of apoptosis regulating proteins and sex hormone receptors in meningiomas. Takei H; Buckleair LW; Powell SZ Neuropathology; 2008 Feb; 28(1):62-8. PubMed ID: 18021195 [TBL] [Abstract][Full Text] [Related]
35. [Expression of HER2/neu in meningiomas: an immunohistochemistry and fluorescence in situ hybridization study]. Wang CL; Mei JH; Wang SS; Xu S; Xu LL; Xiong YF Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):156-60. PubMed ID: 20450760 [TBL] [Abstract][Full Text] [Related]
36. Clinical features and immunohistochemical expression levels of androgen, estrogen, progesterone and Ki-67 receptors in relationship with gross-total resected meningiomas relapse. Tao Y; Liang G; Li Z; Wang Y; Wu A; Wang H; Lu Y; Liu Z; Hu G Br J Neurosurg; 2012 Oct; 26(5):700-4. PubMed ID: 22616825 [TBL] [Abstract][Full Text] [Related]
37. MIB1 proliferation index in meningiomas: does it predict recurrence? A clinicopathological study. Tyagi A; Chakrabarty A; Franks A Br J Neurosurg; 2004 Aug; 18(4):357-61. PubMed ID: 15702834 [TBL] [Abstract][Full Text] [Related]
38. Estrogen and progesterone receptor in meningiomas: An immunohistochemical analysis. Telugu RB; Chowhan AK; Rukmangadha N; Patnayak R; Phaneendra BV; Mowliswara Prasad BC; Reddy MK J Cancer Res Ther; 2020; 16(6):1482-1487. PubMed ID: 33342817 [TBL] [Abstract][Full Text] [Related]
39. Immunocytochemical study of progesterone receptor in human meningioma. Perrot-Applanat M; Groyer-Picard MT; Kujas M Acta Neurochir (Wien); 1992; 115(1-2):20-30. PubMed ID: 1595392 [TBL] [Abstract][Full Text] [Related]
40. Risk Factors for High-Grade Meningioma in Brain and Spine: Systematic Review and Meta-analysis. Shin HK; Park JH; Cho YH; Kim YH; Hong SH; Kim JH; Roh SW; Jeon SR World Neurosurg; 2021 Jul; 151():e718-e730. PubMed ID: 33974984 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]